Urologix, Inc. (ULGX) - OTCPK - No Info
  • Jul. 9, 2015, 4:09 PM
    • Citing the reporting costs and other demands of being a listed company, thinly traded nano cap Urologix (OTCQB:ULGX) terminates its registration with SEC. The move will eliminate the requirement for periodic financial statements and other filings. The stock will trade on the OTC Pink henceforward.
    | Jul. 9, 2015, 4:09 PM
  • Mar. 23, 2015, 12:41 PM
    • Urologix (OTCQB:ULGX) appoints Scott M. Madson as Chief Financial Officer effective April 1. Previously, he was VP, Controller and Chief Accounting Officer for Universal Hospital Services.
    | Mar. 23, 2015, 12:41 PM
  • Jan. 12, 2015, 12:08 PM
    • Urologix (OTCQB:ULGX) reports fiscal Q2 results on February 5 after the close. The conference call will begin at 4:00 pm CT/5:00 pm ET.
    • On a preliminary basis, revenues for the quarter were $3.1M.
    | Jan. 12, 2015, 12:08 PM
  • Nov. 4, 2014, 5:40 PM
    • Urologix (OTCQB:ULGX): FQ1 EPS of -$0.02.
    • Revenue of $3.02M (-20.1% Y/Y).
    | Nov. 4, 2014, 5:40 PM
  • Aug. 19, 2014, 5:17 PM
    • Urologix (ULGX) fiscal Q4 and full year results:
    • Q4: Revenues: $3.3M (-21.3%); Operating Expenses: $5.0M (+56.6%); Net Loss: ($3.5M) (-182.7%); Loss Per Share: ($0.17) (-183.3%); Quick Assets: $0.7M (-68.6%).
    • Fiscal 2014: Revenues: $14.2M (-14.2%); Operating Expenses: $13.0M (+7.6%); Net Loss: ($7.6M) (-77.3%); Loss Per Share: ($0.36) (-71.4%); Cash Burn: ($1.5M) (+21.9%).
    • No financial guidance given.
    | Aug. 19, 2014, 5:17 PM
  • May 2, 2013, 6:26 AM
    Urologix (ULGX): Q1 EPS of -$0.05 beats by $0.01. Revenue of $4.1M beats by $0.25M. (PR)
    | May 2, 2013, 6:26 AM
  • Feb. 6, 2013, 6:23 AM
    Urologix (ULGX): FQ2 EPS of -$0.05 in-line. Revenue of $4.4M (+9.7% Y/Y) beats by $0.4M. (PR)
    | Feb. 6, 2013, 6:23 AM
  • Sep. 6, 2011, 2:30 PM

    Urologix (OTCPK:ULGX +27%) soars after announcing it's signed an exclusive worldwide license to manufacture and market Medtronic's (MDT +0.2%) Prostiva RF Therapy System for the treatment of BPH.

    | Sep. 6, 2011, 2:30 PM
Company Description
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix Cooled ThermoTherapy produces targeted microwave energy combined with a... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States